Please select the option that best describes you:
Would you consider HER2-directed therapy in a patient with pretreated metastatic right sided colon adenocarcinoma progressed on FOLFOX-bevacizumab if they are both HER2-neu amplified and have a HER2-neu exon 19 mutation?
If so, what agent(s) would you consider given the concurrent amplification and mutation?